| Date | Title | Description |
| - | President Obama Views Demonstration of ReWalk Exoskeleton Technology During Visit to Israel | ARGO Medical Technologies’ ReWalk exoskeleton was one of the cutting-edge Israeli inventions demonstrated to President Barack Obama in Israel during his visit to a session hosted by Technion-Israel Institute of Technology. ReWalk inventor D... |
| - | Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company | Jerusalem, Israel, August 19, 2014 — Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG (“Novartis”). Accor... |
| - | ReWalk Robotics announces Australian approval, distribution agreement | ReWalk Robotics has announced a collaboration with Making Strides, of Queensland, Australia. Making Strides will be the first dedicated spinal cord injury recovery center in Australia to distribute ReWalk systems in the country.
ReWalk als... |
| - | First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell’s Ongoing Phase I/II Clinical Trial for Blood Cancers. This is the first transplantation to use a graft of ex... | Jerusalem, Israel, January 8, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that the first person has been successfully transplanted with cryopreserve... |
| - | D-Pharm announces expected date of interim report for the DP-b99 Acute Ischemic Stroke Study, MACSI | D-Pharm Ltd., (TASE: DPRM) announced today that the interim report for the DP-b99 MACSI study is expected in February, 2012. The report will be based on the futility analysis of the data obtained from first 350 patients that complete the fo... |
| - | ARGO Medical Technologies Unveils Advancement of its Exoskeleton Technology with Launch of ReWalk Rehabilitation 2.0 | BERLIN, Jan 29, 2013 (BUSINESS WIRE) — ARGO Medical Technologies has unveiled the newest generation of its ReWalk Rehabilitation exoskeleton that enables individuals with spinal cord injuries the ability to walk again. The 2.0 system is des... |
| - | Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study | Jerusalem, Israel – Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to h... |
| - | NanoPass Technologies Grants a Commercial License to Janssen Pharmaceuticals, Inc., for use of its MicronJet Device | - |
| - | IDRI and Medicago to present data at the World Vaccine Congress Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant | SEATTLE, WA, and QUEBEC CITY, QC, April 9, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Med... |
| - | This Version of the ReWalk Personal Exoskeleton Offers Users the Fastest Walking Speed, Most Natural Gait, and the Most Precise Fit of Any Exoskeleton | YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSETTS, July 14, 2015 — ReWalk Robotics Ltd. (Nasdaq: RWLK), the leading global exoskeleton manufacturer, unveiled today the latest edition of its Personal powered exoskeleton system—the ReWalk Per... |
| - | D Pharm expands Chinese cooperation agreement. The agreement with Wanbang Biopharmaceuticals was extended to a new formulation of D Pharm’s treatment for ischemic stroke | D-Pharm Ltd. (TASE: DPRM) has expanded its commercialization agreement with China’s Wanbang Biopharmaceuticals Ltd. for D Pharm’s leading product, DP-b99 for the treatment of ischemic stroke. D Pharm will receive $7.65 million in milestone ... |
| - | Governor Patrick Joins Israeli-Founded ARGO Medical Technologies to Announce Selection of Massachusetts as U.S. Headquarters | - |
| - | New Era Starts as ReWalk Exoskeleton Technology is Available to Take Home | LONDON–Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use... |
| - | NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products
About Immune Design
About Cancer Immunotherapy | NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle deli... |
| - | OrSense Receives FDA Clearance for its Noninvasive Hemoglobin Monitor | - |
| - | OrSense Non Invasive Hemoglobin Monitor Shown Safe and Accurate for Pre-Donation Screening in Blood Banks | OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that its non-invasive Hemoglobin (Hb) NBM-200 monitor was the topic of multiple recent studies highlighting the clinical value of... |
| - | ReWalk Robotics Announces Reimbursement Coverage by Major German Insurance Company | YOKNEAM ILIT, ISRAEL / BERLIN, GERMANY / MARLBOROUGH, MASSACHUSETTS, September 23, 2014–ReWalk Robotics Ltd. (Nasdaq: RWLK) (d.b.a. Argo Medical Technologies in Germany) announced today that a major German insurance company is the first to ... |
| - | NanoPass Secures Series B Investment to Accelerate Commercialization of its Intradermal Delivery Products | NanoPass Technologies Ltd., a pioneer in the development and commercialization of painless intradermal (skin) delivery solutions for vaccines and large molecules, announced today it has recently closed a new round of financing, led by Israe... |
| - | Gamida Cell plans to commence Phase III study of NiCord in 2016 | Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the company has reached agreements with the FDA and EMA regarding the Phase III study design outline of NiC... |
| - | First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at Duke University | erusalem, Israel, November 12, 2012 — Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enro... |
| - | Gamida Cell Reports StemEx® Phase II/III Study Safety and Efficacy Data | Jerusalem, Israel, — Gamida Cell announced today additional analyses for the Phase II/III, multi-center, multi-national, historical cohort-controlled study to evaluate efficacy and safety of StemEx® as an alternative transplantation treatme... |
| - | ARGO Medical Technologies Announces European Commercial Launch of the ReWalk Exoskeleton for Personal Use ARGO executives and several current users showcase the availability of the ReWalk personal sys... | DUSSELDORF, Germany, Oct 11, 2012 (BUSINESS WIRE) — Exoskeleton technology leader, ARGO Medical Technologies, today announced that its ReWalk is now commercially available for personal use throughout Europe. The company also announced that ... |
| - | Gamida Cell’s NiCord® Receives FDA and EMA Orphan Drug Designation. NiCord® is in clinical development as a treatment for blood cancers including leukemia and lymphoma |
Jerusalem, Israel, January 6, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of He... |
| - | The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma. The results of the StemEx study are expected duri... | Jerusalem, Israel, February 13, 2012 — Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, mul... |
| - | OrSense Non Invasive Hemoglobin Monitor Received CFDA Approval for Marketing in China | - |
| - | Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration | We are witnessing a paradigm shift in transplantation. The first patient was successfully transplanted with a stem cell graft entirely expanded in ex vivo cultures and without the support of a second unit of un-manipulated stem cells. Gamid... |
| - | Agreement Will Launch First Ever Exoskeleton Rehabilitation Programs, Distribution in Northern India | - |
| - | NanoPass Technologies Grants an Exclusive License to Circassia Pharmaceuticals, for use of its MicronJet600™ Device in Allergy Testing in the US | NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600™, its microneedle delivery device, to Circassia P... |
| - | GI View Receives 510(K) FDA Clearance for the Aer-O-Scope™ Colonoscope System for Colorectal Cancer Screening. Aer-O-Scope™ is the only single use, self propelled colonoscope with full 360° Omni-direc... | Ramat Gan, Israel, December 2, 2014, GI View, developer of advanced GI screening systems, announced today that it has received FDA 510(k) clearance for its flagship product, the Aer-O-Scope™, the most advanced and comprehensive system for c... |
| - | OrSense detects hemorrhage, anemia during pregnancy | Israel’s OrSense , a developer of monitors for non-invasive measurements of various blood parameters, announced successful clinical trial results for anemia screening and hemorrhage detection via non-invasive methods. Dr. Eran Hadar, of the... |
| - | ReWalk Announces First U.S. Private Insurance Coverage for Personal System Workers’ Compensation is the First Private Insurer to Provide Payment for an Exoskeleton | Marlborough, MA — January 22, 2015 — Exoskeleton leader ReWalk Robotics announced today the first reimbursement for a personal exoskeleton system by a private U.S. insurer. This coverage comes from a health plan contracted through Workers’ ... |
| - | OrSense Introduces Glasswing, its Next-Generation, Wireless, Non-Invasive Hemoglobin Monitoring System for Anemia Screening | Cancun, Mexico, July 9, 2012 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in C... |
| - | OrSense’s Non-Invasive Hemoglobin Measurement System for Pre-Donation Screening of Anemia Delivers Superior Clinical Value Compared to Current Methods
Representatives of three hospitals and Red Cross... | NES ZIONA, Israel, Oct 20, 2011 — OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that 3 poster presentations on the clinical value of its NBM 200 non-invasive hemoglobin (Hb) m... |
| - | Spaulding Rehabilitation Hospital Launches Exoskeleton Rehabilitation Program with Rewalk Robotics. | Boston, MA – December 5, 2014 – Spaulding Rehabilitation Hospital Boston, one of the leading rehabilitation hospitals in the United States, announced the development of an exoskeleton training program utilizing the ReWalk Robotics exoskelet... |
| - | - |
Gamida Cell , a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product.
NiCord is in development as... |
| - | ReWalk Robotics Ltd. Files Registration Statement for Proposed Initial Public Offering | YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., July 10, 2014 — ReWalk Robotics Ltd. (“ReWalk”) today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public of... |
| - | NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative | - |
| - | - | ReWalk™ Personal Exoskeleton System Cleared by FDA for Home Use
Revolutionary technology that allows individuals with Spinal Cord Injury, such as paraplegia, to stand & walk receives clearance for personal use in the U.S.
Marlborough,... |
| - | - | NEW YORK, Jan. 7, 2013 /PRNewswire via COMTEX/ — Bed Bath & Beyond–the go-to resource for home and beauty–recently added the Silk’n Flash&Go all-over permanent hair removal device to all retail doors in the U.S. and Canada. This exp... |